Dimension Therapeutics, Inc. (DMTX) Cut to Sell at Citigroup Inc.
Dimension Therapeutics, Inc. (NASDAQ:DMTX) was downgraded by Citigroup Inc. from a “neutral” rating to a “sell” rating in a report issued on Tuesday, Marketbeat Ratings reports. They presently have a $5.50 target price on the biotechnology company’s stock, up from their prior target price of $3.41. Citigroup Inc.’s price target indicates a potential downside of 6.78% from the stock’s previous close.
A number of other equities analysts also recently commented on DMTX. Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a report on Monday, August 14th. Cantor Fitzgerald set a $3.00 price objective on Dimension Therapeutics and gave the stock a “hold” rating in a report on Saturday, June 10th. Canaccord Genuity downgraded Dimension Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $12.00 to $3.41 in a report on Wednesday, August 30th. Finally, Zacks Investment Research downgraded Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Dimension Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.13.
Dimension Therapeutics (DMTX) traded up 0.85% during midday trading on Tuesday, hitting $5.90. 108,903 shares of the company traded hands. The company’s market cap is $147.81 million. Dimension Therapeutics has a 12-month low of $1.05 and a 12-month high of $9.62. The stock has a 50 day moving average price of $2.55 and a 200-day moving average price of $1.73.
Dimension Therapeutics (NASDAQ:DMTX) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.49). The company had revenue of $4.37 million for the quarter. Dimension Therapeutics had a negative return on equity of 98.72% and a negative net margin of 358.21%. Analysts expect that Dimension Therapeutics will post ($2.10) EPS for the current year.
A number of institutional investors have recently made changes to their positions in DMTX. Two Sigma Securities LLC bought a new stake in Dimension Therapeutics during the first quarter worth approximately $108,000. Goldman Sachs Group Inc. boosted its position in shares of Dimension Therapeutics by 206.7% in the second quarter. Goldman Sachs Group Inc. now owns 80,471 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 54,231 shares during the period. Finally, Weiss Multi Strategy Advisers LLC boosted its position in shares of Dimension Therapeutics by 6.7% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 390,403 shares of the biotechnology company’s stock valued at $683,000 after acquiring an additional 24,489 shares during the period. 70.75% of the stock is owned by hedge funds and other institutional investors.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.